Paul L. Berns was appointed as President and Chief Executive Officer of Anacor Pharmaceuticals Inc. in 2014. He served as a Board member since 2012 and as Chairman since 2013. Anacor was acquired by Pfizer in June 2016. From March 2006 to September 2012, Mr. Berns served as President and Chief Executive Officer, and member of the board of directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in July 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, which was acquired by Abbott in 2001. From 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Mr. Berns has been a director of Jazz Pharmaceuticals, PLC since June 2010. Mr. Berns received a B.S. in Economics from the University of Wisconsin.

 Ophthalmology